Chiara Pircher

Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial

Michele Reni, Gianpaolo Balzano, Silvia Zanon et al. · ˜The œLancet. Gastroenterology & hepatology · 2018 · 249 citations

Postoperative Chemotherapy, Surgical Oncology, Pancreatic Cancer +8

Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial

Michele Reni, Silvia Zanon, Umberto Peretti et al. · ˜The œLancet. Gastroenterology & hepatology · 2018 · 66 citations

Pancreatic Cancer, Gastrointestinal Oncology, Metastatic Pancreatic Adenocarcinoma +7

A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma

Michele Reni, Silvia Zanon, Gianpaolo Balzano et al. · European Journal of Cancer · 2018 · 57 citations

Surgical Oncology, Oncology, Pancreatic Cancer +9

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)

Giuseppe Procopio, Mélanie Claps, Chiara Pircher et al. · Tumori Journal · 2022 · 46 citations · Full text

Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients

Arsela Prelaj, Edoardo Gregorio Galli, V. Miskovic et al. · Frontiers in Oncology · 2023 · 30 citations · Full text